Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A £210,000 donation from the Alan Davidson Foundation (ADF) has been made to the Nuffield Department of Clinical Neurosciences (NDCN) to advance the University’s world leading research into Motor Neurone Disease (MND). The funding will support a project manager for three years to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis and eventually, prevention of all forms of MND.

Alan Davidson with a dog and an inspirational letter he had written
Alan Davidson - ‘Envisioner of Dreams’ who believed that innovation and investment in science is the key to advancing MND treatment

MND symptoms develop insidiously and the early stages can be similar to other conditions, which means that diagnosis can sometimes take a year or more. As a result, damage to the nervous system can go undetected before physical symptoms become apparent. Professor Talbot and his research group work as part of the Oxford Motor Neurone Disease Centre, linking the research to clinical care.

The team has already established promising approaches to treatment in patients who currently have the disease. The aim of this new ground-breaking research is to identify people at risk of MND before symptoms occur, so that treatment can be applied at the early stages when it can be more effective and disability can be prevented.

About 10% of patients with MND have a genetic mutation and each of their close relatives (parents, siblings and children) will have a 50% chance of carrying the gene that leads to MND. The research funded by ADF will sign up 300 – 400 ‘at risk’ individuals, who will be carefully monitored to enable the team to pick up the very earliest signals of the disease. The ultimate aim is to produce a blood test that could be used in general practice to screen for the silent damage occurring in the early phase of MND. A cohort study of this kind, linking in with the established MND network, will be unique, and once the cohort is in place, major research funding will also be sought to analyse the samples donated by people taking part in the study.

Read the full story on the University of Oxford Development Office website. 

Similar stories

Attention and memory deficits persist for months after recovery from mild Covid

Researchers from Oxford’s Department of Experimental Psychology and Nuffield Department of Clinical Neurosciences have shown that people who have had Covid but don’t complain of long Covid symptoms in daily life nevertheless can show degraded attention and memory for up to 6-9 months.

New book expands the horizons of brain research

A pioneering book from Professor Zoltán Molnár and Yale Professors Tamas Horvath and Joy Hirsch to be released on 1 February 2022 addresses the fundamental relationship between the body, brain and behaviour.

New research sheds light on how ultrasound could be used to treat psychiatric disorders

A new study in macaque monkeys has shed light on which parts of the brain support credit assignment processes (how the brain links outcomes with its decisions) and, for the first time, how low-intensity transcranial ultrasound stimulation (TUS) can modulate both brain activity and behaviours related to these decision-making and learning processes.

Dramatic fall in hospital admissions for child infections since start of Covid-19 pandemic

Since the onset of the Covid-19 pandemic, there have been dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

Rosalind Franklin Institute and Pharmacology announce strategic partnership in Next Generation Chemistry

The Rosalind Franklin Institute and the University of Oxford’s Department of Pharmacology have entered into a strategic partnership for Next Generation Chemistry.

Christoph Treiber awarded ERC Starting Grant to investigate the origins of behavioural diversity

Congratulations are in order for postdoctoral research scientist Dr Christoph Treiber who has been awarded a Starting Grant from the European Research Council. His funded project will investigate the genetic components that may contribute to diversity of brain function and behaviour.